Bruker Corporation (BRKR)

Bruker reported Q3 2025 revenues of $860.5 million, a 0.5% decrease year-over-year, with organic revenue down 4.5%, and non-GAAP diluted EPS was $0.45, exceeding analyst estimates, which led to a stock decrease. Bruker participated in the Nasdaq 2025 London Investor Conference. Bruker's management provided a weak organic revenue growth forecast for 2026 at the J.P. Morgan 44th Annual Healthcare Conference, causing the stock to fall. Guggenheim raised its price target on Bruker's stock to $53.00 from $45.00, leading to a stock gain. Bruker reported Q4 2025 revenues of $977.2 million, flat year-over-year but down approximately 5% organically, and non-GAAP diluted EPS was $0.59, missing analyst expectations, which led to a drop in the stock price. Bruker showcased novel analytical systems and automation technologies at the Analytica 2026 conference, contributing to a stock jump. A fourth-quarter dividend of US$0.05 was announced. Bruker received a consensus "Hold" rating from brokerages.

Demand for Bruker Corp.'s products and services can be influenced by macroeconomic conditions that impact funding for research initiatives, fluctuations in biopharma funding, and the timing of large semiconductor orders. Investment needs can be seasonal, causing temporary swings in free cash flow, and research funding cycles imply that demand for Bruker's scientific instruments and solutions can experience seasonal variations.

Bruker Corp. is an American manufacturer of scientific instruments and analytical and diagnostic solutions, operating in the Healthcare sector, specifically in the Medical Devices and Life Sciences Tools and Services industries. The company's product portfolio includes mass spectrometers, X-ray diffractometers, X-ray tomography devices, NMR spectroscopy devices, fluorescence microscopes, Raman spectroscopes, atomic-force microscopes, profilometers, ICPMS systems, laboratory gas chromatography (GC), GC-triple quadrupole mass spectrometers, and superconducting materials. Bruker's business is segmented into Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST).

Headquartered in Billerica, Massachusetts, Bruker Corp. has a global presence with operations and sales offices worldwide. The company expanded into Europe in the early 1970s, the USSR in 1969, Australia in 1972, and China in 1975. The United States is a key geographic market and generates the maximum revenue for the company.

Bruker has maintained a reputation for innovation and scientific excellence. The company has showcased new analytical systems and automation technologies at major conferences and sponsors prizes like the Fritz Feigl Prize and the Günther Laukien Prize. Bruker's collaborations with academic institutions and research centers further bolster its image as a leader in developing new analytical techniques.

Bruker Corporation's ownership is predominantly held by institutional investors, who collectively own about 80.00% to 81.91% of the company's shares. Key institutional shareholders include T. Rowe Price Investment Management, Inc., Vanguard Fiduciary Trust Co., and BlackRock, Inc. Frank H. Laukien, the Chairman, President, and CEO, is the largest individual stockholder, holding approximately 25.62% to 26.69% of shares. Other Laukien family members also hold significant stakes, contributing to a substantial collective insider ownership.